CORDIS - EU research results
CORDIS

A new and innovative method to extract adipose Stromal Vascular Fraction: Application in post-prostatectomy erectile dysfunction

Project description

New stem cell therapy treats erectile dysfunction after prostatectomy

Erectile dysfunction (ED) remains common following radical prostatectomy. Recent clinical studies have shown that stromal vascular fraction, a therapy made of stem cells that are harvested from the adipose tissue found in our bodies, offers renewed hope. The EU-funded STEMCIS project developed a unique kit that isolates the adipose cells and regenerates damaged tissues. Building on this work, the MECADISTEM project is developing a single-use kit that includes all the necessary tools to rapidly (less than 30 minutes) extract adipose tissue progenitor cells mechanically. Researchers aim to fast-track development for rapid commercialisation and improved quality of life for both the patient and his partner.

Objective

Erectile dysfunction (ED) is a significant and common medical problem which impairs quality of life of men and their partners. ED is a frequent complication after a radical prostatectomy (RP) due to surgical treatment for prostate cancer. For this condition, ED represents a significant unmet medical need, since there is no efficient treatment to repair the cellular damages following a RP. Clinical implementation of stem cell treatment represents a potential candidate for ED treatment after RP. Adult progenitor cells extracted from adipose tissue, called Stromal Vascular Fraction (SVF) have shown promising results in preclinical and clinical studies to treat post-RP ED. STEMCIS has developed a unique kit to isolate the adipose cells which hold the potential to cure post-prostatectomy ED by regenerating the damaged tissues. MECADISTEM comes in the form of a single-use kit that includes all the tools necessary to simply and rapidly (less than 30 minutes) extract adipose tissue progenitor cells mechanically (grinding, centrifugation, filtration). Compared to the state-of-the-art alternatives using “collagenase (enzymatic) digestion”, MECADISTEM does not require the use of enzymes, avoiding the problems and constraints imposed by the use of this enzymatic digestion and offering substantial time and money savings, on both technical and surgical operations. Having validated this methodology in preclinical study, this project is planned to finalise the development and market preparation of this kit. In this Phase 1 Feasibility Study, we aim to evaluate the main milestones of the project from a technical, commercial and financial point of view. Once in the market, MECADISTEM will be used by urologists and surgeons to cure ED in patients following a RP, where the current therapies have not been proven effective. It will secure the growth for STEMCIS, expecting to gain over €12 million in profits, hire 6 new people and reach a ROI of €6.28 from this project after 5 years.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

STEMCIS SAS
Net EU contribution
€ 50 000,00
Address
2 RUE MAXIME RIVIERE
97490 SAINTE CLOTILDE
France

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
RUP FR — Régions Ultrapériphériques Françaises La Réunion La Réunion
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00